
Related news and events
Inmagene Biopharmaceuticals Completes Merger With Ikena Oncology [UPDATED]
Egnyte Announces Majority Investment From GI Partners and TA Associates
Admissions and credentials
New York
Experience
2025 07 25 Inmagene
July 25, 2025
Cooley advised Inmagene Biopharmaceuticals, a privately held, global clinical-stage biotechnology company developing novel therapeutics for immunological and inflammatory diseases, on its definitive merger agreement with Ikena Oncology (Nasdaq: IKNA).
Related contacts
Related Practices & Industries
Cerberus Announces Landmark Investment in Aquatech
April 3, 2025
Cooley advised Cerberus Capital Management, a global leader in alternative investing with approximately $65 billion in assets across complementary credit, real estate and private equity strategies, on its growth investment in Aquatech, a global leader in water technology and services for industrial and infrastructure markets.
Related contacts
Related Practices & Industries
Egnyte Announces Majority Investment From GI Partners and TA Associates
February 25, 2025
Cooley advised Egnyte, a provider of secure content collaboration and governance solutions, on its strategic growth investment from GI Partners and TA Associates.
Related contacts
Related Practices & Industries
H1 Acquires Ribbon Health
January 8, 2025
Cooley advised H1, a global healthcare data technology company, on its acquisition of Ribbon Health.
Related contacts
Related Practices & Industries
Inmagene Biopharmaceuticals Announces Merger With Ikena Oncology
December 23, 2024
Cooley advised Inmagene Biopharmaceuticals, a privately held, global clinical-stage biotechnology company developing novel therapeutics for immunological and inflammatory diseases, on its definitive merger agreement with Ikena Oncology (Nasdaq: IKNA).